Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Umbilical Cord-mesenchymal Stem Cells in End-stage Liver Diseases
NCT06167473Completed
- Sponsor
- General Hospital of the Northern Theater Command
- Start
- Nov 2023
- Primary completion
- Dec 2025
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Randomised trial of umbilical cord-mesenchymal stem cells in liver disease (2 arms), sponsored by General Hospital of the Northern Theater Command. Primary endpoint: Survival rate at 1 year. Started Nov 2023; status: completed.
02
Drugs
umbilical cord-mesenchymal stem cells
03
Conditions
liver disease
Beyond the preview
Go deeper on NCT06167473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06167473.